Edgewise Therapeutics (EWTX) Assets Average (2021 - 2026)

Edgewise Therapeutics has reported Assets Average over the past 6 years, most recently at $535.6 million for Q1 2026.

  • Quarterly results put Assets Average at $535.6 million for Q1 2026, up 13.8% from a year ago — trailing twelve months through Mar 2026 was $535.6 million (up 13.8% YoY), and the annual figure for FY2025 was $519.7 million, up 25.71%.
  • Assets Average reached $535.6 million in Q1 2026 per EWTX's latest filing, down from $568.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $598.4 million in Q3 2025 and bottomed at $265.1 million in Q2 2022.
  • Median Assets Average over the past 5 years was $446.9 million (2024), compared with a mean of $428.9 million.
  • The largest annual shift saw Assets Average dropped 13.76% in 2022 before it skyrocketed 62.45% in 2024.
  • Over 5 years, Assets Average stood at $372.1 million in 2022, then fell by 12.48% to $325.7 million in 2023, then surged by 53.22% to $499.0 million in 2024, then increased by 13.82% to $568.0 million in 2025, then fell by 5.72% to $535.6 million in 2026.
  • Business Quant data shows Assets Average for EWTX at $535.6 million in Q1 2026, $568.0 million in Q4 2025, and $598.4 million in Q3 2025.